Vertex Pharmaceuticals stock price closed the week on a positive note, gaining 2.66% on Friday. VRTX stock price closed the week at $48.16 a share. VRTX has traded in a 52 week range from $31.25 to $52.13 per share.
Vertex Pharmaceuticals' drug pipeline includes Telaprevir (VX-950) for the treatment of hepatitis C virus (HCV). Telaprevir is currently in Phase III clinical trials. VRTX also a Phase III clinical trial candidate named VX-770 for the treatment of cystic fibrosis.
Vertex Pharmaceuticals is a member of the Nasdaq 100. VRTX is based in Cambridge, Massachusetts and has over 1600 employees.
Vertex Pharmaceuticals
